Covid out Clinical Trial

#covid19 #drugstudies #clinicaltrials #drugcombinations #drugdesign #diabetes Published in the New England Journal of Medicine, researchers — led by the University of Minnesota Medical School and School of Public Health — have found that metformin, a commonly prescribed diabetes medication, lowers the odds of emergency department visits, hospitalizations, or death due to COVID-19 by over 40 percent; and over 50 percent if prescribed early in the onset of symptoms. The study also found no positive effect from treatment with either ivermectin or low-dose fluvoxamine. The study design was simple — patients were randomly assigned to receive one of the three drugs individually, placebo, or a combination of metformin and fluvoxamine or metformin and ivermectin. Although the study was placebo-controlled with exact-matching placebo pills, Dr. Carolyn Bramante, the study’s lead author says that 83% of volunteers received medications supported by existing data because of the six-arm design. Each participant received 2 types of pills to keep their treatment assignment masked, for 3 to 14 days of treatment. Each volunteer tracked their symptoms, and after 14 days, they completed a survey. Get the latest medical and health news at medicaldialogues.in Follow us on Twitter:   / medicaldialogs   Facebook:   / medicaldialogues   Instagram:   / medicaldialogues   LinkedIn:   / medical-dialogues   Website: https://medicaldialogues.in/